Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics
- PMID: 15068979
- DOI: 10.7326/0003-4819-140-7-200404060-00011
Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics
Abstract
Background: A response to proton-pump inhibitors (PPIs) is commonly considered to support the diagnosis of gastroesophageal reflux disease (GERD). However, the accuracy of this diagnostic strategy has not been well established.
Objective: To estimate the diagnostic test characteristics of successful PPI treatment with objective measures of GERD by performing a meta-analysis based on the published literature.
Data sources: English-language studies were identified by searching the Cochrane Clinical Trial Register and MEDLINE from 1 January 1980 through 1 July 2003.
Study selection: Studies in which the clinical response to a short course (1 to 4 weeks) of normal- or high-dose PPI therapy could be compared with objective measures of GERD (24-hour pH monitoring, endoscopy findings, symptom questionnaires).
Data extraction: Studies were screened for inclusion by 1 author. Final decisions on exclusion were made by consensus with 2 of the other authors. Two investigators independently extracted the data. Information extracted included patient characteristics, study design, setting, specific type and dose of medication, duration of treatment, and definitions of outcomes.
Data synthesis: Sensitivity and specificity were determined by comparing a clinical response to PPIs with objective measures for GERD. The summary receiver-operating characteristic curve method was used to summarize test characteristics across studies. Sensitivity and specificity were also combined independently by using a random-effects model. Fifteen studies met the inclusion criteria and provided sufficient data. With 24-hour pH monitoring as the reference standard, the positive likelihood ratio ranged from 1.63 to 1.87, and combined estimates of sensitivity and specificity were 0.78 (95% CI, 0.66 to 0.86) and 0.54 (CI, 0.44 to 0.65), respectively. These values were lower with the other reference standards.
Limitations: Data were insufficient to determine the effect of various doses of PPIs and duration of therapy on test characteristics.
Conclusion: Successful short-term treatment with a PPI in patients suspected of having GERD does not confidently establish the diagnosis when GERD is defined by currently accepted reference standards.
Comment in
-
Summaries for patients. Does symptom response diagnose gastroesophageal reflux disease?Ann Intern Med. 2004 Apr 6;140(7):I51. doi: 10.7326/0003-4819-140-7-200404060-00004. Ann Intern Med. 2004. PMID: 15069004 No abstract available.
-
Limitations of gold standards for diagnosing gastroesophageal reflux disease.Ann Intern Med. 2004 Oct 19;141(8):648; author reply 648-9. doi: 10.7326/0003-4819-141-8-200410190-00019. Ann Intern Med. 2004. PMID: 15492348 No abstract available.
Similar articles
-
[Trial therapy with proton pump inhibitors is not a suitable test for gastroesophageal reflux disease; a meta-analysis of the diagnostic test characteristics].Ned Tijdschr Geneeskd. 2004 Sep 25;148(39):1924-8. Ned Tijdschr Geneeskd. 2004. PMID: 15495992 Review. Dutch.
-
The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):423-7. doi: 10.1586/egh.10.38. Expert Rev Gastroenterol Hepatol. 2010. PMID: 20678016
-
Summaries for patients. Does symptom response diagnose gastroesophageal reflux disease?Ann Intern Med. 2004 Apr 6;140(7):I51. doi: 10.7326/0003-4819-140-7-200404060-00004. Ann Intern Med. 2004. PMID: 15069004 No abstract available.
-
Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.Dis Esophagus. 2013 Jul;26(5):443-50. doi: 10.1111/j.1442-2050.2012.01381.x. Epub 2012 Aug 2. Dis Esophagus. 2013. PMID: 22862422
-
Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.Gastroenterol Clin North Am. 2020 Sep;49(3):437-450. doi: 10.1016/j.gtc.2020.04.003. Epub 2020 Jun 14. Gastroenterol Clin North Am. 2020. PMID: 32718563 Review.
Cited by
-
Improving treatment of people with gastro-esophageal reflux disease refractory to proton pump inhibitors.Commun Med (Lond). 2024 Oct 14;4(1):200. doi: 10.1038/s43856-024-00632-6. Commun Med (Lond). 2024. PMID: 39397153 Free PMC article. Review.
-
Prevalence of Gastroesophageal Reflux Disease and Its Impact on the Quality of Life Among Obese Individuals in Al-Baha Region, Saudi Arabia.Cureus. 2024 Jun 24;16(6):e63073. doi: 10.7759/cureus.63073. eCollection 2024 Jun. Cureus. 2024. PMID: 38933342 Free PMC article.
-
Refractory Gastroesophageal Reflux Disease: Diagnosis and Management.J Neurogastroenterol Motil. 2024 Jan 30;30(1):17-28. doi: 10.5056/jnm23145. J Neurogastroenterol Motil. 2024. PMID: 38173155 Free PMC article. Review.
-
Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population.Cureus. 2023 Nov 18;15(11):e48994. doi: 10.7759/cureus.48994. eCollection 2023 Nov. Cureus. 2023. PMID: 38111444 Free PMC article.
-
Noninvasive, MultiOmic, and Multicompartmental Biomarkers of Reflux Disease: A Systematic Review.Gastro Hep Adv. 2023;2(4):608-620. doi: 10.1016/j.gastha.2023.01.014. Epub 2023 Jan 21. Gastro Hep Adv. 2023. PMID: 38009162 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous